Companies › NextCure
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SIM0505 for injection | – | Phase 1 | Advanced Solid Tumors | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06792552 | SIM0505 for injection | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2028 |
Cash of $15m on 2026-06-30; operating cash outflow about $47m a year; runway about 4 months at that burn, to Oct 2026
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.